Drugs / WTX-330
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05678998 | Dec 2022 → Dec 2024 | non-Hodgkin lymphoma | Werewolf Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06939283 | May 2025 → Aug 2028 expected | non-Hodgkin lymphoma | Werewolf Therapeutics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2025-12-18 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Announces Pipeline and Business Updates werewolftx.com ↗
WTX-330 Phase 1b/2 trial initial data demonstrated additional evidence of antitumor activity and highly favorable tolerability profile, building upon monotherapy activity demonstrated in first-in-human Phase 1 clinical trial |
| 2025-11-07 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting werewolftx.com ↗ |
| 2024-11-07 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting werewolftx.com ↗
Preliminary clinical findings presented at SITC demonstrate WTX-330’s promising therapeutic potential as a monotherapy, exhibiting a favorable tolerability profile and inducing tumor shrinkage in patients with treatment-resistant solid tumors, including those tumors that are less sensitive to immunotherapy. |
| 2024-10-04 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting werewolftx.com ↗
The tumor-activated IL-12 prodrug WTX-330 expanded/activated tumor infiltrating lymphocytes and caused tumor regression in patients with refractory solid tumors: Interim data from an ongoing Ph1 study |
| 2024-06-25 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma werewolftx.com ↗ |
| 2023-04-19 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research werewolftx.com ↗
mWTX-330 treatment generates a robust, cleavage-dependent anti-tumor immune response in multiple syngeneic tumor models and is well tolerated. |
| 2022-11-10 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting werewolftx.com ↗
Study data demonstrate that systemic administration of mWTX-330, a mouse surrogate INDUKINE molecule, generates potent anti-tumor activity in a cleavage-dependent manner and protective memory against re-challenge in multiple murine syngeneic tumor models. |
| 2022-04-08 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Meeting werewolftx.com ↗
WTX-330 surrogate demonstrated significant expansion of the therapeutic window, compared to recombinant IL-12, and generated potent anti-tumor immunity in multiple syngeneic tumor models |
| 2021-12-01 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics to Present Preclinical Data on INDUKINE™ Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting werewolftx.com ↗ |
All press releases naming this drug 10 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WTX-330 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06939283 ↗ |
| Modality | Protein / enzyme biologic | “a conditionally-activated IL-12 prodrug” NCT05678998 ↗ |